|1.||Merlos, Manuel: 3 articles (02/2009 - 11/2007)|
|2.||Román, Juan: 3 articles (02/2009 - 11/2007)|
|3.||Comalada, Mònica: 3 articles (02/2009 - 11/2007)|
|4.||Gálvez, Julio: 3 articles (02/2009 - 11/2007)|
|5.||Zarzuelo, Antonio: 3 articles (02/2009 - 11/2007)|
|6.||Ramis, Isabel: 3 articles (02/2009 - 11/2007)|
|7.||Bailón, Elvira: 3 articles (02/2009 - 11/2007)|
|8.||Michelena, Pedro: 2 articles (02/2009 - 07/2008)|
|9.||Nieto, Ana: 2 articles (07/2008 - 11/2007)|
|10.||Concha, Angel: 2 articles (07/2008 - 11/2007)|
07/01/2008 - "Moreover, the different results obtained by UR-1505 in these 2 protocols of colitis induction (acute initial colitis versus established colitis) confirm the importance of selection and optimization of the experimental model to evaluate the drugs to be used in IBD therapy."
07/01/2008 - "UR-1505, a salicylate able to selectively block T-cell activation, shows intestinal anti-inflammatory activity in the chronic phase of the DSS model of rat colitis."
11/15/2007 - "The intestinal anti-inflammatory effects of the novel agent UR-1505 in the TNBS model of rat colitis are mediated by T-lymphocyte inhibition."
11/15/2007 - "This study describes the anti-inflammatory activity of UR-1505 on trinitrobenzenesulphonic acid-induced colitis in rat, an experimental model that resembles to Crohn's disease (CD), as well as its in vitro effects on T-cells and bone marrow-derived macrophages (BMDM) activation. "
02/01/2009 - "The aim of the present study was to evaluate the inmunomodulatory effects of UR-1505, a new salicylate derivative, on the T helper (Th)2/humoral response produced during dextran sodium sulfate (DSS)-induced rat colitis. "
09/01/2015 - "No serious nor causal adverse reactions were reported in this study, but patients reported numerous local symptoms after product applications, especially itching, tingling, tightness, and heat/burning sensations at frequencies that were similar for vehicle, 1% UR-1505, and 2% UR-1505; more frequent with 0.5% UR-1505; and lowest for tacrolimus. "
|3.||Atopic Dermatitis (Atopic Eczema)
09/01/2015 - "Safety and Activity of UR-1505 in Atopic Dermatitis: A Randomized, Double-blind Phase II Exploratory Trial."
09/01/2015 - "We compared the activity of UR-1505 ointment against its vehicle in the treatment of atopic dermatitis. "
09/01/2015 - "This study found that UR-1505 may not be a suitable option for the treatment of atopic dermatitis due to its lack of clinically relevant effect compared with its vehicle and 0.1% tacrolimus ointment."
|4.||Crohn Disease (Crohn's Disease)
07/01/2008 - "The results obtained demonstrated that although UR-1505 did not exert a significant intestinal anti-inflammatory effect in ameliorating the initial steps of the intestinal inflammation induced by DSS, it had a beneficial effect on ongoing inflammation, most probably through inhibiting activation of T lymphocytes, thus avoiding perpetuation of the inflammatory process. "
09/01/2015 - "UR-1505 is a new small molecule with immune modulator properties intended for the topical treatment of inflammatory skin diseases that has shown anti-inflammatory effects in models of skin inflammation. "
02/01/2009 - "However, in contrast to the in vitro results, the administration of UR-1505 (10 and 30 mg/kg per day) to rats with established DSS-colitis enhanced both IL-10 and IgA production, whereas it inhibited IgG production, thus ameliorating the intestinal inflammation."
|2.||2- hydroxy- 4- (2,2,3,3,3- pentafluoropropoxy)benzoic acid
|3.||sodium sulfate (sodium bisulfate)
|5.||Interleukin-10 (Interleukin 10)
|7.||Immunoglobulin G (IgG)
|8.||Immunoglobulin A (IgA)